ACW Actinogen Medical Ltd
- 0.026
- -0.001-3.70%
Actinogen Medical Ltd News
Actinogen Medical Opens AU$3.9 Million Entitlement Offer; Shares Down 7%
Actinogen Medical (ASX:ACW) on Wednesday opened its AU$3.9 million 1-for-15 entitlement offer priced at AU$0.025 per share. Proceeds will be used to advance the XanaMIA trial in patients with mild to
Actinogen Medical Lodges Prospectus for Nearly AU$4 Million Entitlement Offer
Actinogen Medical (ASX:ACW) lodged the prospectus for a 1-for-15 entitlement offer priced at AU$0.025 per share to raise up to AU$3.9 million. The shares come with 1-for-2 options that expire May 31,
Actinogen Medical Completes Patient Enrolment for XanaCIDD Phase 2a Trial; Shares Up 3%
Actinogen Medical (ASX:ACW) completed enrolment of 167 participants in its XanaCIDD phase 2a clinical trial in patients with cognitive impairment in major depressive disorder, according to a Monday fi
Actinogen Medical Launches Alzheimer's Trial to Test Impact of Xanamem on Cognitive Health
Actinogen Medical (ASX: ACW) has treated the first subject in its clinical trial of patients with biomarker-positive mild to moderate Alzheimer’s disease.
Actinogen Doses First Patient in Phase 2b Alzheimer's Disease Trial; Shares Rally 16%
Actinogen Medical (ASX:ACW) dosed the first patient in its phase 2b clinical trial investigating the use of the medication Xanamem in patients with mild to moderate forms of Alzheimer's disease, accor
Actinogen Medical With Proactive at ASX Small and Mid Cap Conference | ASX:ACW, OTC:ATGGF
Actinogen Medical Notifies of Errors on M&A Slide in Recent Presentation
Actinogen Medical (ASX:ACW) has notified shareholders that a slide concerning large M&A deals for Karuna Therapeutics and Cerevel Therapeutics in Dec. 2023 incorrectly referred to the deals as lead as
Investors in Actinogen Medical (ASX:ACW) Have Unfortunately Lost 53% Over the Last Year
Actinogen Medical Initiates Final Enrolment Phase for XanaCIDD Depression Trial; Shares Rise 3%
Actinogen Medical (ASX:ACW) commenced the enrollment of participants in its Phase 2a trial of XanaCIDD for cognitive impairment and depression, surpassing 80% with a total of 129 participants, accordi
Actinogen Medical on Track to Deliver Two Key Phase 2 Trial Results in Next 18 Months
Actinogen Medical Ltd (ASX:ACW, OTC:ATGGF) is advancing two major Phase 2 clinical trial programs using its novel therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol.
Actinogen Medical Secures UK Innovation Passport for Alzheimer's Disease Treatment
Actinogen Medical (ASX:ACW) secured an innovation passport from the UK Medicines and Healthcare Products Regulatory Agency for the Alzheimer's Disease treatment Xanamem. The passport serves as the ent
Actinogen Medical Activates First Trial Site for Phase 2B Alzheimer's Disease Trial
Actinogen Medical (ASX:ACW) activated the first trial site for its phase 2b trial investigating the use of its lead medication Xanamem in patients with mild to moderate Alzheimer's disease. The placeb
Actinogen Medical's XanaCIDD Trial Enrolment Surpasses 50% Milestone
Actinogen Medical (ASX:ACW) said Tuesday that its enrolment in the XanaCIDD Phase 2a trial, which involves 160 participants with cognitive impairment associated with persistent major depressive disord
Actinogen Medical Redesigns Phase 2b Trial of Alzheimer's Disease Drug
Actinogen Medical (ASX:ACW) said it has enhanced the design of the XanaMIA Phase 2b trial in patients with mild-to-moderate Alzheimer's to reduce the cost and time to initial results. The current so-c
Stocks of the Hour: Lake Resources, Talon Energy, Actinogen Medical
Lake Resources (ASX:LKE) has announced a successful completion of the lithium carbonate test program, which is an important milestone towards the completion of DFS. In response,Lake CEO David Dickson
Actinogen Medical Completes AU$10 Rights Issue
Actinogen Medical (ASX:ACW) said it has concluded its AU$10 million non-renounceable rights offer, with the sale of 400,057,938 new shares. These stocks will be issued on September 11. Proceeds will b
Actinogen Medical to Raise AU$10 Million for Clinical Trial Program; Shares Down 22%
Actinogen Medical (ASX:ACW) is seeking to raise about AU$10 million to advance its clinical trial program on the treatment of cognitive impairment, depression and Alzheimer's disease. The funding will
Investors in Actinogen Medical (ASX:ACW) Have Made a Strong Return of 215% Over the Past Three Years
Here's Why We're Not Too Worried About Actinogen Medical's (ASX:ACW) Cash Burn Situation
Actinogen Medical (ASX:ACW) Receives FDA Approval for Six-month Phase 2b Alzheimer Trial
Analysis
Price Target
No Data
